Drug intelligence / Profile preview

CF04

Development stage: Unknown
Lead developer: Shanghai Puyou Biopharmaceutical
Administration: Ophthalmic

Overview

CF04 is a drug candidate initially developed by Shanghai Amphiprotech. It is currently in Phase 2 clinical development, with its primary therapeutic area being eye diseases. Specific details about its mechanism of action, molecular target, or modality have not been disclosed in the available sources. The drug appears to be an investigational pharmaceutical intended for ophthalmic indications[1].

Targets

FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)

Beyond the preview

Go deeper on CF04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF04.

Explore the full profile